8-K: Theriva Biologics Amends Sales Agreement, Updates At-the-Market Offering

Theriva Biologics has amended its sales agreement with A.G.P./Alliance Global Partners to update its at-the-market offering and terminated its agreement with B. Riley Securities.

Summary

• Theriva Biologics has entered into Amendment No. 2 to its sales agreement with A.G.P./Alliance Global Partners, effective May 2, 2024.
• This amendment updates the registration statement reference to a new shelf registration statement on Form S-3 filed on May 2, 2024, or any subsequent S-3 filing.
• The company may offer and sell shares of its common stock through A.G.P./Alliance Global Partners in an at-the-market offering.
• The company also terminated its sales agreement with B. Riley Securities, Inc. on May 1, 2024.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. It details a routine update to a sales agreement and a termination of an agreement, which are not inherently positive or negative. The ability to continue to raise capital is a positive, but the loss of a sales agent is a slight negative.

Positives

• The amendment allows Theriva Biologics to continue to access capital through an at-the-market offering.
• The company has updated its registration statement to a new Form S-3, which may provide more flexibility in future offerings.

Negatives

• The termination of the agreement with B. Riley Securities, Inc. reduces the number of sales agents available to the company.

Risks

• The company's ability to raise capital through at-the-market offerings depends on market conditions and investor demand.
• The termination of the agreement with B. Riley Securities, Inc. could potentially limit the company's access to capital.

Future Outlook

The company may offer and sell shares of its common stock through A.G.P./Alliance Global Partners in the future under the updated agreement.

Management Comments

• Steven A. Shallcross, Chief Executive Officer and Chief Financial Officer, signed the amendment on behalf of Theriva Biologics, Inc.

Industry Context

At-the-market offerings are a common method for biotech companies to raise capital, and this amendment allows Theriva Biologics to continue to utilize this strategy.

Comparison to Industry Standards

• Many small-cap biotech companies use at-the-market offerings to raise capital, similar to Theriva Biologics.
• The use of a shelf registration statement on Form S-3 is a standard practice for companies that plan to issue securities over time.
• The termination of an agreement with one sales agent while maintaining another is not uncommon in the industry.

Stakeholder Impact

• Shareholders may experience dilution if the company issues new shares through the at-the-market offering.
• The company's ability to raise capital may impact its ability to fund operations and research.

Next Steps

• The company may proceed with at-the-market offerings of its common stock through A.G.P./Alliance Global Partners.
• The company will utilize the new Form S-3 registration statement for future offerings.

Key Dates

Keywords

at-the-market offering, sales agreement, Theriva Biologics, A.G.P./Alliance Global Partners, B. Riley Securities, common stock, Form S-3, capital raise